Merck's Pneumococcal Vaccine Gets FDA Nod for High-Risk Youth

What happened

The FDA approved an expanded label for Merck's pneumococcal vaccine (Capvaxive) to include children and adolescents aged 2-17 with chronic conditions that increase pneumococcal disease risk. While this extends the vaccine's addressable population, the incremental revenue is modest relative to Merck's $65B+ top line. The approval supports the narrative that new launches like Capvaxive can contribute to offsetting headwinds, but it does not materially alter the company's heavy reliance on Keytruda (49% of 2025 sales) or the unresolved Gardasil-China overhang.

Implication

Capvaxive adds to the launch portfolio needed to bridge post-2028 revenue erosion, but the approval was widely anticipated. Sustained upside requires broader vaccine uptake and evidence that new products collectively fill the Keytruda gap.

Thesis delta

The approval incrementally strengthens the vaccine franchise but does not shift the core thesis. Merck still faces a ~$2.5B FY2026 headwind, China Gardasil uncertainty, and an impending Keytruda exclusivity cliff. The thesis remains WAIT until proof of launch scaling and Gardasil resolution emerge.